Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.88+0.09 (+0.92%)

Close on Nov 13, 2026Market cap $104.25MP/E –Yield –

Biodesix price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Biodesix's price to sales ratio was 1.0× on Nov 11, 2026, against 0.8× a year earlier. Over the last 5 years it ranged from 0.7× to 93.4×, with a median of 38.5×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.0×	+0.4
2025	Dec 31, 2025	0.7×	−67.2
2024	Dec 31, 2024	67.9×	−5.9
2023	Dec 29, 2023	73.8×	+20.9
2022	Dec 30, 2022	52.9×	+14.4
2021	Dec 31, 2021	38.5×	+34.1
2020	Dec 31, 2020	4.4×	–

Where these numbers come from

Parsed from the XBRL in Biodesix's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Sep 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDSX.

Compare: BDSX vs MDXH · BDSX vs PSNL · BDSX vs CSTL · BDSX vs XGN · BDSX vs GRAL

Revenue growth31.2% · median 15.3%

Operating margin-18.7% · median -88.4%

Net margin-25.7% · median -86.4%

Company	Revenue	Growth
CSTL	$377.13M	+9.8%
GRAL	$166.60M	+17.5%
BDSX	$105.21M	+31.2%
PSNL	$80.77M	+16.9%
XGN	$72.30M	+13.7%
MDXH	–	–

Company

Next earnings (est.): Feb 25, 2027, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 334
Held by institutions: 41.4%
Auditor: KPMG LLP
SEC CIK: 1439725

Advertisement
300 × 250

See a number that looks wrong?